Human Blood, Leukopaks & Apheresis Products
PBMCs, leukopaks and isolated immune subsets from apheresis donors, including recallable donor programmes.
| Category | Native & Primary Tissue to Spec |
|---|---|
| Unit | One leukopak, one specimen, or one prospectively collected lot |
| Lead time | 2 weeks from banked inventory; quote-dependent and considerably longer for prospective collection and recallable-donor draws |
| Pricing | By quotation |
| Provenance | Custom RFQ |
| Data current | 2026-09-01 |
Description
Consented human blood-derived material, supplied fresh or cryopreserved. HemaCare operates apheresis collection supplying PBMCs, leukopaks, mobilised leukopaks and isolated immune subsets, and its differentiator is a recallable donor programme allowing repeat draws from the same individual, which removes donor as a variable across a longitudinal design in a way no inventory purchase can. iSpecimen reaches the same material through a marketplace over hospitals, biorepositories, practice groups, commercial laboratories and health information exchanges, and its structural claim is contractual rather than biological: one contract covering hundreds of providers, with iSpecimen managing contracting and compliance across every contributor site. Anyone who has assembled a multi-institution cohort knows the paperwork rather than the material sets the schedule. Sanguine recruits patients directly and collects to the buyer's own protocol under IRB, specifying cohort, tube type, timepoints and processing window, and catalogues disease-specific fluids including rheumatoid arthritis and osteoarthritis synovial fluid. The question that decides which of the three to use is whether the pre-analytical variable is part of the experiment: if time to freeze, anticoagulant choice or processing method is a factor you are measuring, buy prospective collection and fund the recruitment; if it is not, standing inventory is the correct answer and prospective collection is money wasted. Nothing in this category is publicly priced, because a quote is a function of cohort definition rather than of catalogue.
Why this is hard to buy today
Two of the three principal suppliers block automated price and inventory retrieval entirely, so a buyer cannot compare cohort feasibility across vendors without opening three parallel sales conversations, and the recallable-donor capability that would remove donor as a variable is not something a first-time buyer knows to ask for.
Price evidence
No supplier of human blood, leukopak or apheresis products publishes a price. HemaCare, iSpecimen and Sanguine were all checked on 2026-09-01: two of the three block automated retrieval and all three route to a quote. We do not estimate one.
These are supplier list prices we located and recorded, not a quotation from Wetware World. Your price depends on quantity, specification and freight, and is only binding once issued in writing.
What you must specify
A quote cannot be produced without these. Anything you leave open, a supplier will assume — usually expensively.
| # | Parameter |
|---|---|
| 01 | Product class (whole blood, PBMC, leukopak, mobilised leukopak, bone marrow aspirate, isolated immune subset) |
| 02 | Fresh versus cryopreserved, and the acceptable time from draw to receipt |
| 03 | Donor demographics, HLA type and disease state |
| 04 | Recallable donor requirement for longitudinal or repeat-draw designs |
| 05 | Cell yield or volume per unit, and the number of unique donors |
| 06 | Anticoagulant, tube type and processing window where the pre-analytical variable is part of the experiment |
| 07 | Banked inventory versus prospective collection under IRB |
| 08 | Consent scope required (research use, commercial use, genomic analysis) |
| 09 | Matched clinical annotation or serology required |
Quality documentation
Typically available with this item. What actually ships is confirmed on the quotation, per supplier.
- Donor consent and IRB documentation
- Serology / infectious disease screening per supplier protocol
- Viability and cell count at release
- Chain-of-custody and collection-to-processing time record
Candidate suppliers
Organisations we have identified as capable. Listing does not imply a partnership, an endorsement, or that they have agreed to quote.
| Organisation | Basis for inclusion |
|---|---|
| HemaCare (Charles River) | Apheresis collection supplying PBMCs, leukopaks, mobilised leukopaks and isolated immune subsets, fresh or cryopreserved, with a recallable donor programme allowing repeat draws from the same individual. No published price; the site blocked automated retrieval on 2026-09-01. |
| iSpecimen | Marketplace over hospitals, biorepositories, practice groups, commercial labs and health information exchanges. The structural claim is contractual rather than biological: one contract, hundreds of providers, with iSpecimen managing contracting and compliance across contributor sites. Specimen classes include leukopaks, mobilised leukopaks, bone marrow aspirate, PBMCs and BMMCs. Quote path only. Live-verified 2026-09-01. |
| Sanguine Biosciences | Direct-to-patient recruitment collecting to the buyer's protocol under IRB: cohort, tube type, timepoints and processing window. Disease-specific fluids including rheumatoid and osteoarthritis synovial fluid. Site returned a Cloudflare challenge on 2026-09-01, so this rests on published descriptions rather than a live fetch. |
| Discovery Life Sciences | Large biospecimen inventory across tissue, blood and disease-state samples; custom prospective collection is their stated core model. Quote-driven. |
Sources
doc WW-NT-24700 · rev 2026-09-01 · research use only · prices indicative and not binding until quoted in writing